Jin Yang, Xiong Xianzhi, Su Yuan, Hu Jianwu, Tao Xiaonan
Department of Pulmonary Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
J Huazhong Univ Sci Technolog Med Sci. 2009 Aug;29(4):462-5. doi: 10.1007/s11596-009-0414-8. Epub 2009 Aug 7.
To examine the relationship between the levels of the serum vascular endothelial growth factor (VEGF) and the micrometastasis of peripheral blood in patients with non-small cell lung cancer (NSCLC), 108 NSCLC patients, including 40 patients with benign lung diseases and 30 healthy controls, were investigated. The serum VEGF levels were detected by ELISA and CK19 mRNA in peripheral blood by reverse transcriptase-polymerase chain reaction (RT-PCR). In NSCLC group, the serum VEGF levels and the positive rate of CK19 mRNA in peripheral blood were 479.8+/-268.5 pg/mL and 66.7%, which were significantly higher than those of the other two groups respectively (P<0.01), and both of them were increased significantly with the progression of clinical stage of the tumors (P<0.01). Serum VEGF levels as well as the positive rate of CK19 mRNA in different pathological types of lung cancer had no significant differences (P>0.05). Serum VEGF levels in the patients positive for CK19 mRNA was 561.7+/-325.6 pg/mL. It is significantly higher than that in the negative patients (P<0.01). There existed a significant correlation between serum VEGF levels and expression of CK19 mRNA in peripheral blood in NSCLC patients (P<0.001). The detection of serum VEGF levels and CK19 mRNA in peripheral blood is helpful in judging the condition and the prognosis of NSCLC patients, and serum VEGF levels and CK19 mRNA are independent of the pathological types of lung cancer. The micrometastasis in peripheral blood of NSCLC patients is significantly associated with serum VEGF levels.
为探讨非小细胞肺癌（NSCLC）患者血清血管内皮生长因子（VEGF）水平与外周血微转移的关系，对108例NSCLC患者、40例肺部良性疾病患者及30例健康对照者进行了研究。采用酶联免疫吸附测定（ELISA）法检测血清VEGF水平，逆转录聚合酶链反应（RT-PCR）法检测外周血CK19 mRNA。NSCLC组血清VEGF水平及外周血CK19 mRNA阳性率分别为479.8±268.5 pg/mL和66.7%，均显著高于其他两组（P<0.01），且二者均随肿瘤临床分期进展而显著升高（P<0.01）。不同病理类型肺癌患者的血清VEGF水平及CK19 mRNA阳性率无显著差异（P>0.05）。CK19 mRNA阳性患者的血清VEGF水平为561.7±325.6 pg/mL，显著高于阴性患者（P<0.01）。NSCLC患者血清VEGF水平与外周血CK19 mRNA表达存在显著相关性（P<0.001）。检测外周血血清VEGF水平及CK19 mRNA有助于判断NSCLC患者的病情及预后，且血清VEGF水平及CK19 mRNA与肺癌病理类型无关。NSCLC患者外周血微转移与血清VEGF水平显著相关。
